VistaGen Therapeutics Announces Proposed Public Offering of Common Stock
VistaGen Therapeutics, Inc. (NASDAQ: VTGN) has announced an underwritten public offering of common stock, subject to market conditions. The company aims to utilize the proceeds for the continued development of its central nervous system (CNS) pipeline, general research, working capital, and corporate purposes. Maxim Group LLC serves as the sole book-running manager for the offering. This offering is made under an effective shelf registration statement, and a preliminary prospectus supplement will be filed with the SEC.
- Intended use of proceeds for CNS pipeline development.
- Solely focused on funding future research and operational costs.
- Potential dilution of existing shares due to new stock issuance.
- Uncertainty surrounding the completion and terms of the offering.
SOUTH SAN FRANCISCO, Calif., July 31, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced it has commenced an underwritten public offering of shares of its common stock. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. VistaGen currently intends to use the net proceeds from the offering to fund continued development of its CNS pipeline programs, and for general research and development, working capital and general corporate purposes.
Maxim Group LLC is acting as sole book-running manager for the offering.
The public offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-234025), previously filed with the U.S. Securities and Exchange Commission (SEC) on September 30, 2019 and declared effective on October 7, 2019. The securities may be offered only by means of a prospectus. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the public offering will be filed with the SEC, will form a part of the effective registration statement and will be available on the SEC's website at www.sec.gov. When available, copies of the preliminary prospectus supplement and accompanying prospectus relating to the public offering may also be obtained by contacting Maxim Group LLC, at 405 Lexington Avenue, 2nd Floor, New York, NY 10174, Attention: Prospectus Department, [or] by telephone at (212) 895-3745 or by email at syndicate@maximgrp.com.
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About VistaGen
VistaGen Therapeutics, Inc. ("VistaGen") is a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and certain CNS diseases and disorders where current treatments are believed by VistaGen to be inadequate, resulting in high unmet need. Each of VistaGen's three drug candidates has a differentiated mechanism of action, an exceptional safety profile in all clinical studies to date, and therapeutic potential in multiple CNS markets. For more information, please visit www.vistagen.com and connect with VistaGen on Twitter, LinkedIn and Facebook.
Forward Looking Statements
Certain of the statements made in this press release are forward-looking, such as those, among others, relating to our expectations regarding the completion of the proposed public offering. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, risks and uncertainties related to whether or not we will be able to raise capital through the sale of shares of common stock, the final terms of the proposed public offering, market and other conditions, the satisfaction of customary closing conditions related to the proposed public offering and the impact of general economic, industry or political conditions in the United States or internationally. There can be no assurance that we will be able to complete the proposed public offering on the anticipated terms, or at all. We will need to raise additional capital to fund our operations and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our product development programs or commercialization efforts. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. Certain other risks are more fully discussed in the section entitled "Risk Factors" in our most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in our other filings with the SEC. Our SEC filings are available on the SEC's website at www.sec.gov. In addition, any forward-looking statements represent our views only as of the issuance of this release and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.
View original content to download multimedia:http://www.prnewswire.com/news-releases/vistagen-therapeutics-announces-proposed-public-offering-of-common-stock-301104127.html
SOURCE VistaGen Therapeutics
FAQ
What is VistaGen Therapeutics planning with the public offering of VTGN stock?
Who is managing VistaGen's public offering?
When was the public offering for VTGN announced?
What are the risks associated with VistaGen's public offering?
Where can I find more information about VistaGen's SEC filings?
